Switch theme
Sign up to access all valuation multiples
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
2021
531
Last FY Revenue n/a
LTM EBITDA -$64.6M
$551M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Recbio has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$64.6M.
In the most recent fiscal year, Recbio achieved revenue of n/a and an EBITDA of -$58.9M.
Recbio expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Recbio valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$64.6M | XXX | -$58.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$77.1M | XXX | -$71.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$82.0M | XXX | -$71.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $64.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 4, 2025, Recbio's stock price is HKD 8 (or $1).
Recbio has current market cap of HKD 3.8B (or $490M), and EV of HKD 4.3B (or $551M).
See Recbio trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $551M | $490M | XXX | XXX | XXX | XXX | $-0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 4, 2025, Recbio has market cap of $490M and EV of $551M.
Recbio's trades at n/a EV/Revenue multiple, and -9.4x EV/EBITDA.
Equity research analysts estimate Recbio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Recbio has a P/E ratio of -6.5x.
See valuation multiples for Recbio and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $490M | XXX | $490M | XXX | XXX | XXX |
| EV (current) | $551M | XXX | $551M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -9.3x | XXX | -9.4x | XXX | XXX | XXX |
| EV/EBIT | -7.8x | XXX | -7.7x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -6.5x | XXX | -6.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRecbio's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.1M for the same period.
Recbio's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Recbio's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Recbio and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -15% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Recbio acquired XXX companies to date.
Last acquisition by Recbio was XXXXXXXX, XXXXX XXXXX XXXXXX . Recbio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Recbio founded? | Recbio was founded in 2021. |
| Where is Recbio headquartered? | Recbio is headquartered in Hong Kong. |
| How many employees does Recbio have? | As of today, Recbio has 531 employees. |
| Is Recbio publicy listed? | Yes, Recbio is a public company listed on HKG. |
| What is the stock symbol of Recbio? | Recbio trades under 02179 ticker. |
| When did Recbio go public? | Recbio went public in 2022. |
| Who are competitors of Recbio? | Similar companies to Recbio include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Recbio? | Recbio's current market cap is $490M |
| Is Recbio profitable? | Yes, Recbio is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Recbio? | Recbio's last 12 months EBITDA is -$64.6M. |
| What is the current EV/EBITDA multiple of Recbio? | Current EBITDA multiple of Recbio is -9.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
